How Open Science Is Keeping Allergan's R&D Pipeline Strong

Allergan's chief R&D officer David Nicholson discusses the company's "open science model" to innovation and innovating, and highlights some of the promising device-based technologies it recently acquired and is developing.

Innovation is a key pillar in the growth strategy of any life-sciences company, but according to David Nicholson, chief research and development officer of specialty pharmaceutical firm Allergan PLC, it is also the biggest challenge.

"You need to focus, you need to interact with the external world and make sure the pipeline is full of...

More from Ophthalmology

More from Device Area